key: cord-0702963-26vlwr6l
authors: Feingold, Brian; Berman, Pamela; Moninger, Allison; Huston, Allison; Stinner, Brenda; West, Shawn C.; Rose‐Felker, Kirsten; Zinn, Matthew D.; Miller, Susan A.; Michaels, Marian G.
title: Responsiveness to second and third dose of mRNA COVID‐19 vaccination in adolescent and young adult heart transplant recipients
date: 2022-03-27
journal: Pediatr Transplant
DOI: 10.1111/petr.14272
sha: 039e0ebc8f736d7539445e83580dd41fbc6f2a01
doc_id: 702963
cord_uid: 26vlwr6l

BACKGROUND: Third‐dose mRNA COVID‐19 vaccine is currently recommended in the United States for SOT recipients based in part on data showing diminished immune response, including Ab production, after a two‐dose regimen. Data on vaccine response in adolescent and young adult SOT recipients are limited, including no data reported on third‐dose responsiveness. METHODS: Results of serologic testing in a convenience sample of 28 vaccinated adolescent and young adult HT recipients at a single institution were collected from the medical record and summarized. RESULTS: At a median of 98.5 days (IQR 59–150) after second dose, 17 (61%) had an Ab response. Among 12 who had serology before and after third‐dose vaccination, four of seven who were negative prior to third dose became positive at a median of 34 days (IQR 31–39.5) following third dose. No myocarditis, acute rejection, graft dysfunction, graft loss, or deaths were observed. CONCLUSIONS: These findings support recommendations for the routine administration of three doses of mRNA vaccines in adolescent and young adult HT recipients and show a potential subpopulation in whom the fourth dose should be contemplated.

A third dose of the COVID-19 mRNA vaccine is recommended in the United States for SOT recipients based in part on data showing poor immune response, including Ab production, after a two-dose regimen. [1] [2] [3] [4] [5] [6] Presently, data on responsiveness to COVID-19 mRNA vaccination in adolescent SOT recipients consist of a handful of reports showing diminished Ab production after a two-dose regimen among predominantly liver and renal transplant recipients (73%) relative to healthy adolescents. [7] [8] [9] [10] We sought to characterize Ab production in response to mRNA vaccination, including response to third-dose vaccination, in a convenience sample of adolescent and young adult HT recipients.

Research Protections Office (PRO19050115) and no informed consent was required. All clinical data were abstracted from clinical care records. Ab data were abstracted from the electronic medical record after provider prescribed testing or given to the care team by Pt/parents for consideration in care decisions when obtained by a nontransplant team provider. We recommended serologic assessment around third-dose vaccination for age-eligible recipients to guide decision-making about timing of vaccination based on the lack of data on COVID-19 vaccine responsiveness in this population, the higher incidence of COVID-19 mRNA vaccine-associated myocarditis in adolescents and young adults, and the age-related lower risk of severe COVID-19. Only some recipients obtained this recommended testing. Ab determinations were made using commercially available, semiquantitative SARS-CoV-2 IgG spike protein assays (R Elecsys Anti-SARS-CoV-2 S, Siemens SARS-CoV-2 IgG, and BC Access SARS-CoV-2 IgG Ab test). [11] [12] [13] Symptoms after vaccine doses were provided by free response from the Pt/parent to a specific inquiry from the transplant nurse coordinator or physician provider during clinical interactions.

Symptoms were not routinely assessed after each vaccine dose nor, when assessed, were they assessed at a specific time after vaccination.

Data were collected through October 31, 2021. Data are presented as median (IQR) or count (%). Comparisons were tested using Mann-Whitney U or Fisher's exact test, as appropriate. Univariable logistic regression was used to assess for relationship between the presence of Ab after second vaccine dose and age at HT, time from HT to vaccination, and time from second dose to Ab assessment.

All statistical comparisons were performed using StataSE 14.0 (StataCorp) and significance assessed by two-sided alpha <0.05.

We identified 59 pediatric and young adult HT recipients (31% F) who received at least two doses of an mRNA COVID-19 vaccine.

Median age at HT was 5.9 years (IQR 0.6-14.0), median age at firstdose vaccination was 17.9 years (IQR 15.2-22.1), and time from HT to first dose was 10.8 years (IQR 5.7-15.9). Of these, 28 individuals (48%) had serologic testing following second-dose vaccination (Table 1 ). There was no difference in demographics between those with or without serology except that fewer who received the Mo prednisone (n = 1, 4%); tac and azathioprine (n = 1, 4%); tac and sirol (n = 1, 4%); and sirol and prednisone (n = 1, 4% In a convenience sampling of symptoms occurring after each vaccine dose among all vaccine recipients, most recipients did not report any symptoms after their first vaccine dose (n = 33, 56%).

The most common symptoms after the first dose were sore arm (n = 15, 25%), fatigue (n = 7, 12%), headache (n = 33, 5%), and fever/feverish, dyspnea, anorexia/gastrointestinal upset, site pain, and nausea (each n = 1, 2%). After second and third doses, the proportion with no symptoms decreased to 44% (n = 26) and 13%

(n = 4), respectively, while sore arm (n = 16, 27%; n = 7, 22%) and fatigue (n = 10, 17%; n = 6, 19%) were most prevalent. In one F 

In this single-center analysis, 61% of adolescent and young adult HT recipients had detectable SARS-CoV-2 spike protein Ab at a median of just over 3 months from second-dose vaccination. This is far below TA B L E 2 Characteristics of and Ab response among adolescent and young adult HT recipients who received three doses of mRNA COVID-19 vaccine All (n = 12) Positive after third dose (n = 9)

Age at HT (years) 7.9 (4.5-11.0) 6.3 (5.9-9.9) 0. 16 Although we found no significant difference in response to second-dose vaccination between those taking and not taking an antimetabolite, this may reflect limited statistical power given our small sample size rather than a true lack of association as has been observed in prior studies. 1, 7, 8 Our findings are noteworthy because they provide additional data on Ab production after second dose, data on ISx regimen, dosing, and trough levels, and novel third-dose response data in adolescent and young adult transplant recipients.

Prevention guidance is for SOT recipients ages 12 and older to receive a fourth (booster) vaccine dose at ≥5 months after completion of a three-dose primary vaccination series. 17 Our data show that at least some adolescent HT recipients will remain negative after a three-dose series. Future recommendations for this age group will need to consider this finding, clinical outcomes of this group, and future developments in the pandemic.

Limitations of our study include the small sample size, free response data collection regarding side effects, and heterogeneity of ISx regimens, timing of Ab assessments relative to vaccine doses, and Ab assessment assays. Specifically regarding vaccine side effect reporting, our methodology prohibits direct comparison to data reported from other studies that was collected in a prospective, standardized manner. Also, there were individuals in our care who were vaccinated but did not have Ab assessments. However, we did not find any relationships between Ab presence/absence after second siveness to the PB vaccine has been generally excellent. 14, 15 In summary, we observed SARS-CoV-2 spike protein Ab production after the second dose of mRNA vaccination in adolescents and young adult HT recipients is inferior to age-matched peers, but akin TA B L E 3 Characteristics and response to the third dose of COVID-19 mRNA vaccine among adolescent and young adult HT recipients without Ab production following second dose to what has been reported in similar-sized cohorts of adolescent SOT, mostly liver and renal, SOT recipients as well as a larger cohort of older adult SOT recipients. Third-dose vaccination prompted Ab production among seronegative recipients, though some still remain negative after third-dose vaccination, indicative of a subpopulation in whom the fourth dose should be contemplated. We observed no serious adverse events associated with mRNA vaccination. These findings support recommendations for routine administration of three doses of mRNA vaccines in adolescent and young adult HT recipients.

The authors of this manuscript have no conflicts of interest to disclose.

Brian Feingold conceptualized the study, analyzed the data, drafted the manuscript, and critically revised the manuscript. Pamela 

Data available on request, contingent on the authors' institutional policies governing such conveyance due to privacy/ethical restrictions.

Antibody response to 2 dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients

Poor anti-SARS-CoV-2 humoral and T-cell responses after 2 injections of mRNA vaccine in kidney transplant recipients treated with belatacept

Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus

Immunogenicity of the BNT162b2 mRNA vaccine in heart transplant recipients-a prospective cohort study

Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients

Antibody response to mRNA SARS-CoV-2 vaccine among kidney transplant recipients-prospective cohort study

Antibody response to 2-dose SARS-CoV-2 mRNA vaccination in pediatric solid organ transplant recipients

Serological response to the BNT162b2 COVID-19 mRNA vaccine in adolescent and young adult kidney transplant recipients

Immunologic response of mRNA SARS-CoV-2 vaccination in adolescent kidney transplant recipients

SARS-CoV-2 anti-spike antibodies after vaccination in pediatric heart transplantation: A first report

Beckmann Coulter ACCESS SARS-CoV-2 IgG Immunoassay

US Food and Drug Administration. Siemens Healthineers Atellica IM Analyzer SARS-CoV-2 IgG Immunoassay. Accessed

Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents

Evaluation of the BNT162b2 covid-19 vaccine in children 5 to 11 years of age

Three doses of an mRNA covid-19 vaccine in solid-organ transplant recipients

Responsiveness to second and third dose of mRNA COVID-19 vaccination in adolescent and young adult heart transplant recipients